Acknowledgements
We would like to thank Dr. Oloruntoba Oluboka (University of Calgary) and Dr. Ofer Agid (University of Toronto) who provided consultation and advice on the design of the ReLiAM study. We would also like to thank the following principal investigators at the participating sites: Dr. Ranjith Chandrasena, Dr. Leandro Cortese, Dr. Lois Ligate, Dr. Marc André Roy, Dr. Heather Milliken, Dr. Alexander McIntyre, Dr. Jean-Pierre Melun, Dr. Rebecca Carriere, Dr. Adekunle Garba Ahmed, Dr. Thomas Raedler, Dr. Rajendra Harricharan, Dr. Roumen Milev, Dr. Ridha Joober, Dr. Sunny Johnson, Dr. Soma Ganesan, Dr. Ashok Malla, and Dr. Jean-François de La Sablionnière. We would also like to thank Kataka Medical Communication for medical writing, editorial and administrative assistance.
Funding
The ReLiAM study and this post-hoc analysis were funded by Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.
Availability of data and materials
For ethical reasons, to ensure the privacy of the patient-level data utilized in the current study, and for reasons related to data ownership by the sponsor, data cannot be made available. However, data could be made available upon request for the purpose of conducting meta-analytic review in future.
Authors’ contributions
HCM, MB, FT and GC contributed to the interpretation of data provided through revisions to the manuscript at all stages. All authors approved the final manuscript.
Ethics approval and consent to participate
All patients signed an informed consent form before any study related procedures were performed for the ReLiAM study. Central Ethics approval was obtained from IRB Services, Aurora, Ontario, Canada. In addition, approval from local institutional ethics boards (University of Windsor, McGill University Health Centre, Institut Universitaire en Sante Mentale de Quebec, Capital Health, Ottawa Health Science Network, Royal Ottawa Health Care Group, University of Calgary, Western University, Queen’s University, Douglas Mental Health Institute, University of British Columbia) was obtained as required.
Competing interests
HCM has received research/grant support from the Montreal General Hospital Foundation, Aifred health, Lundbeck, Otsuka and SyneuRx; and has received honoraria as a paid speaker and/or consultant for AbbVie, HLS Therapeutics, Janssen, Lundbeck, Otsuka, and Sunovion. MB is a full-time employee of Otsuka Canada Pharmaceutical Inc. and affiliate member of the Department of Pharmacology & Therapeutics, Faculty of Medicine and Health Sciences at McGill University, Montreal, Canada.
FT is a full-time employee of Otsuka Canada Pharmaceutical Inc.
GC was a full-time employee of Lundbeck Canada Inc at the time of this analysis.
Consent for publication
Not applicable